What's Happening?
Teva Canada has announced that Health Canada has approved an expanded indication for PrAJOVY (fremanezumab solution for subcutaneous injection) for the prevention of episodic migraine in pediatric patients aged 6 to 17 years. This makes PrAJOVY the first and only calcitonin gene-related peptide (CGRP) antagonist approved for this age group. The approval is based on the results of the Phase 3 SPACE trial, which demonstrated significant reductions in monthly migraine days for pediatric patients. This development marks a significant advancement in expanding preventive treatment options for children and adolescents living with migraine.
Why It's Important?
The approval of PrAJOVY for pediatric use addresses a significant gap in migraine treatment for children and adolescents,
who have historically had limited preventive options. This expansion not only provides a new treatment avenue for young patients but also underscores Teva's commitment to addressing neurological challenges across all age groups. The availability of PrAJOVY for pediatric patients could lead to improved quality of life for affected families, reducing the impact of migraines on education and social participation.
